BeyondSpring (BYSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Sep, 2026Executive summary
The annual general meeting is scheduled for October 13, 2026, with both in-person and virtual participation options available.
Shareholders of record as of August 24, 2026, are entitled to vote on meeting matters.
Proxy materials are accessible online, with options for paper or electronic delivery upon request.
Voting can be conducted via Internet, mail, or during the virtual/in-person meeting, with a deadline for Internet voting set at 11:59 p.m. ET on October 12, 2026.
Voting matters and shareholder proposals
The primary proposal is the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders may also vote on any other matters that properly come before the meeting.
Shareholders holding at least 10% of voting share capital may requisition an extraordinary general meeting.
Proposals for inclusion in the next annual meeting proxy must be received by May 6, 2027; director nomination notices are due by August 14, 2027.
Audit committee and external auditor matters
The audit committee is responsible for appointing and overseeing the independent auditors, including evaluating their qualifications and independence.
CBIZ was engaged as auditor after acquiring Marcum LLP’s attest business; no disagreements or reportable events occurred during the transition.
Marcum’s prior audit reports included a going concern explanatory paragraph for 2023 but no adverse opinions.
A simple majority of votes cast is required to ratify CBIZ’s appointment.
Representatives from CBIZ are expected to attend the AGM and respond to questions.
Latest events from BeyondSpring
- Plinabulin and SEED's molecular glue platform drive late-stage oncology innovation and commercial potential.BYSI
Investor presentation - Shareholders will vote on auditor ratification at the October 2026 annual meeting.BYSI
Proxy filing - Plinabulin and SEED's TPD platform deliver innovative, clinically validated solutions for hard-to-treat cancers.BYSI
Corporate presentation - Plinabulin's strong NSCLC survival data drives DUBLIN-4 focus amid $5.7M Q2 net loss and funding needs.BYSI
Q2 2026 - Plinabulin and SEED's TPD platform offer transformative potential for cancer care and beyond.BYSI
Corporate presentation - Q1 2026 net loss was $6.7M, cash at $7.9M, and Plinabulin advanced as an ADC agent.BYSI
Q1 2026 - Plinabulin achieved Phase 3 survival benefit in NSCLC; financials strengthened and pipeline advanced.BYSI
Q4 2025 - Biopharma firm registers 10M shares for R&D and corporate use, facing clinical and financial risks.BYSI
Registration Filing - Up to 10M shares registered for flexible sale to fund R&D amid ongoing financial uncertainty.BYSI
Registration Filing